Necrotizing Gingivostomatitis Treatment Market - Top Companies and Manufacturers

  • Report ID: 3570
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Companies Dominating the Necrotizing Gingivostomatitis Treatment Landscape

    • Novartis International AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Abbott Laboratories
    • Eli Lilly and Company
    • Hindustan Antibiotics Limited
    • Aviro Health L.P.

Browse Key Market Insights with Data Illustration:

In the News

  • GlaxoSmithKline plc conducted an online survey in five European countries with 4,500 people to study the relationship between poor oral hygiene and disease complications. The conclusion of the study showed that there was a need to raise public awareness regarding the impact of oral hygiene on overall health.

  • Aviro Health L.P. declared that it granted the award of investigator-initiated research (IIR) grant to the University of Pennsylvania School of Dental Medicine Center for Clinical and Translational Research to investigate and report the effectiveness of povidone-iodine antiseptic oral rinse in removing COVID-19 virus or SARS-CoV-2 virus in the mouth.


Author Credits:  Radhika Pawar


  • Report ID: 3570
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of necrotizing gingivostomatitis treatment is estimated at USD 16.94 Million.

The necrotizing gingivostomatitis treatment market size was valued at USD 15.99 Million in 2023 and is anticipated to cross USD 36.7 Million by the end of 2036, expanding at more than 6.6% CAGR during the forecast period i.e., between 2024-2036. Increasing incidences of necrotizing gingivostomatitis and the rising use of public toilets are the major factors driving the market growth.

North America is poised to be the largest with a share of about 39% by 2036, attributed to high prevalence of lifestyle diseases, caused by inactive routines, busy lifestyles, and unhealthy eating habits.

Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited, Aviro Health L.P.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample